Unknown Author
January 24, 2026
Kirkland Advises Cinven and Bioclinica on Merger with ERT

1 min
AI-made summary
- Kirkland & Ellis advised Cinven and its portfolio company Bioclinica on Bioclinica's merger with ERT, a global provider of clinical end-point data solutions
- Following the transaction, Cinven will hold a significant minority stake in ERT, partnering with Nordic Capital, Astorg, and Novo Holdings A/S
- The financial terms were not disclosed
- The Kirkland team included partners and associates from transactional, tax, debt finance, and antitrust practices.
Kirkland & Ellis advised international private equity firm Cinven and its portfolio company Bioclinica, a leading integrated solutions provider of clinical life science and technology expertise, on the merger of Bioclinica with ERT, a global leader in clinical end-point data solutions. As part of the transaction, Cinven will become a significant minority shareholder of ERT working in partnership with Nordic Capital, Astorg and Novo Holdings A/S. Financial terms of the transaction were not disclosed. Read the press release from Cinven The Kirkland team was led by transactional partner Laura Sullivan, and included transactional partner Sean Rodgers and associates Brooke Coghlan, Amanda Gottlieb and Alan Heisman, tax partners Sara Zablotney and Vivek Ratnam, debt finance partner Jud Oswald and antitrust partners Matt Reilly and Mike DeRita and associate Sam Morelli.
Article Author
Unknown Author
The Sponsor
